These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 28577293)
1. Pharmacokinetics of Bevacizumab in Three Patients Under the Age of 3 Years with CNS Malignancies. Gojo J; Sauermann R; Knaack U; Slavc I; Peyrl A Drugs R D; 2017 Sep; 17(3):469-474. PubMed ID: 28577293 [TBL] [Abstract][Full Text] [Related]
2. Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation. Han K; Peyret T; Quartino A; Gosselin NH; Gururangan S; Casanova M; Merks JH; Massimino M; Grill J; Daw NC; Navid F; Jin J; Allison DE Br J Clin Pharmacol; 2016 Jan; 81(1):148-60. PubMed ID: 26345283 [TBL] [Abstract][Full Text] [Related]
3. Feasibility and tolerability of bevacizumab in children with primary CNS tumors. Reismüller B; Azizi AA; Peyrl A; Heinrich M; Gruber-Olipitz M; Luckner D; Rothschild KV; Slavc I Pediatr Blood Cancer; 2010 May; 54(5):681-6. PubMed ID: 20066713 [TBL] [Abstract][Full Text] [Related]
4. Add-on-therapy with bevacizumab in children and adolescents with poor prognosis non-CNS solid tumors. Pansy J; Fritsch P; Sovinz P; Lackner H; Schwinger W; Urban C; Benesch M Anticancer Drugs; 2013 Feb; 24(2):198-203. PubMed ID: 23154263 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154 [TBL] [Abstract][Full Text] [Related]
6. Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo. Pinter M; Ulbrich G; Sieghart W; Kölblinger C; Reiberger T; Li S; Ferlitsch A; Müller C; Lammer J; Peck-Radosavljevic M Radiology; 2015 Dec; 277(3):903-12. PubMed ID: 26131911 [TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of bevacizumab in cancer patients with external validation. Han K; Peyret T; Marchand M; Quartino A; Gosselin NH; Girish S; Allison DE; Jin J Cancer Chemother Pharmacol; 2016 Aug; 78(2):341-51. PubMed ID: 27329360 [TBL] [Abstract][Full Text] [Related]
8. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Shih T; Lindley C Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999 [TBL] [Abstract][Full Text] [Related]
9. A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects. Hettema W; Wynne C; Lang B; Altendorfer M; Czeloth N; Lohmann R; Athalye S; Schliephake D Expert Opin Investig Drugs; 2017 Aug; 26(8):889-896. PubMed ID: 28651442 [TBL] [Abstract][Full Text] [Related]
10. Bevacizumab safety in patients with central nervous system metastases. Besse B; Lasserre SF; Compton P; Huang J; Augustus S; Rohr UP Clin Cancer Res; 2010 Jan; 16(1):269-78. PubMed ID: 20028762 [TBL] [Abstract][Full Text] [Related]
11. Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. Lassen U; Chinot OL; McBain C; Mau-Sørensen M; Larsen VA; Barrie M; Roth P; Krieter O; Wang K; Habben K; Tessier J; Lahr A; Weller M Neuro Oncol; 2015 Jul; 17(7):1007-15. PubMed ID: 25665807 [TBL] [Abstract][Full Text] [Related]
12. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. Glade Bender JL; Adamson PC; Reid JM; Xu L; Baruchel S; Shaked Y; Kerbel RS; Cooney-Qualter EM; Stempak D; Chen HX; Nelson MD; Krailo MD; Ingle AM; Blaney SM; Kandel JJ; Yamashiro DJ; J Clin Oncol; 2008 Jan; 26(3):399-405. PubMed ID: 18202416 [TBL] [Abstract][Full Text] [Related]
13. A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men. Markus R; Chow V; Pan Z; Hanes V Cancer Chemother Pharmacol; 2017 Oct; 80(4):755-763. PubMed ID: 28864922 [TBL] [Abstract][Full Text] [Related]
14. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB. Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709 [TBL] [Abstract][Full Text] [Related]
15. Safety of bevacizumab in patients younger than 4 years of age. Millan NC; Poveda MJ; Cruz O; Mora J Clin Transl Oncol; 2016 May; 18(5):464-8. PubMed ID: 26318053 [TBL] [Abstract][Full Text] [Related]